Corrigendum to ‘Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer’ [International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635]
The authors wish to revise certain aspects of the article to ensure alignment with the final published RAMP 201 study data. The paragraph below has been updated to reflect the new data and should read:
Authors
- Cassidy Blaiss
- Erin Hickey Zacholski
- Sarah Hayward
- Jennifer MacDonald
Institutions
- Medical University of South Carolina (US)
- Virginia Commonwealth University (US)
- MUSC Hollings Cancer Center (US)
- Oklahoma State University Oklahoma City (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2026-06-12
- DOI
- https://doi.org/10.1016/j.ijgc.2026.104763
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00